Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Astellas Pharma (4503 JP): Growth Momentum Intact in Q1; FY27 Guidance Reiterated

Astellas Pharma (4503 JP): Izervay Approved In Japan, Strategic Brands Will Be Key In Near Future

Astellas Pharma (4503 JP): Strategic Brands Gain Further Momentum, Margins Expand, Guidance Revised

Astellas Pharma (4503 JP): Strong H1FY26 Performance Leads to Upward Revision of FY26 Guidance

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/astellas-pharma-inc" target="_blank" data-smartkarma-citation="entities:6091:1" rel="noopener">Astellas Pharma (4503 JP)</a> reported 12% YoY revenue growth in FY26. Core operating profit increased to ¥555.7B, up 42% YoY driven by cost optimization through sustainable margin transformation program.</li>
<li>Strategic brands (Padcev, Izervay, Veozah, Vyloy, Xospata), which recorded underlying growth of 43% YoY and contributed 22% of revenue, drove overall revenue growth. Xtandi attains peak sales.</li>
<li>Astellas unveiled FY27 guidance where they expect FY27 revenue to be ¥2,220B (up 3.8% YoY), core operating profit of ¥620B (up 11.6% YoY) and core profit of ¥460B (+8.4% YoY).</li>
</ul>



Astellas Pharma (4503 JP) reported 12% YoY revenue growth in FY26. Core operating profit increased to ¥555.7B, up 42% YoY driven by cost optimization through sustainable margin transformation program.
Strategic brands (Padcev, Izervay, Veozah, Vyloy, Xospata), which recorded underlying growth of 43% YoY and contributed 22% of revenue, drove overall revenue growth. Xtandi attains peak sales.
Astellas unveiled FY27 guidance where they expect FY27 revenue to be ¥2,220B (up 3.8% YoY), core operating profit of ¥620B (up 11.6% YoY) and core profit of ¥460B (+8.4% YoY).


Astellas Pharma (4503 JP): Strategic Brands Shine in FY26 as Xtandi Peaks, FY27 Guidance Revealed